News | Stents Bioresorbable | July 11, 2016

University Hospitals Case Medical Center First in Midwest to Implant Abbott Absorb Stent

Cleveland hospital one of 50 sites nationwide launching the fully bioresorbable stent

Abbott, Absorb bioresorbable stent, University Hospitals Case Medical Center, first Midwest implant

July 11, 2016 — University Hospitals Case Medical Center, Cleveland, is among the first in the country – and the first in Ohio — to offer and deploy the Abbott Absorb stent, a completely bioresorbable stent. The Absorb stent works exactly as its traditional metallic predecessors in that it opens a blocked coronary artery, with one major exception — it dissolves completely in the body two to three years after implantation.

On July 8, University Hospitals (UH) implanted its first Absorb dissolving stent on a patient with coronary artery disease. UH is one of 50 sites around the nation who will launch the Absorb product.

Recently approved by the U.S. Food and Drug Administration (FDA), Absorb is the first and only fully dissolving stent approved for the treatment of coronary artery disease, which impacts over 15 million people in the United States and is the world's leading cause of death.

Made of naturally dissolving material, the new device provides the same benefits as traditional stents and trial data supports its potential benefits in restoring long-term vessel function. The stent utilizes the same cath lab equipment already in place and study data supports comparable healing with the traditional metallic stent.

Hiram Bezerra, M.D., and Gui Attizzani, M.D., of the UH Harrington Heart & Vascular Institute, played a significant role in assisting Abbott in bringing this technology to market.  

"Absorb is a new, potentially game-changing therapy for coronary artery disease," said Bezerra, medical director, Cardiovascular Imaging Core Laboratory – UH Harrington Heart & Vascular Institute. "While it may never totally replace traditional DES [drug-eluting stents], this novel technology gives us the ability to repair a patient's artery with comparable healing and safety and reduces long-term complications."

Like traditional metallic DES, Absorb opens a patient's blocked artery but then disappears after leaving no metal behind to restrict natural vessel motion. Absorb is made of polyactic acid similar to material used in dissolving sutures. Through the process of hydrolysis, the scaffold is metabolized after two to three years.

In clinical studies conducted throughout the world, the new stent demonstrated comparable short-term and mid-term outcomes compared to the leading metallic stent. After the first year of the clinical trial of approximately 2,000 patients in the United States (Absorb III randomized trial), patients who received the Absorb experienced comparable rates of specific adverse events in the intended patient population. 

It also eliminates the need for layer upon layer of metal in a situation where patients experience in-stent restenosis. Additionally it reduces the amount of metal in the coronary arteries when the patient requires multiple stents.

"The device restores vasomotor function and pulsatility allowing the artery to move and more naturally regulate blood flow," said Bezerra, who is also assistant professor, medicine, Case Western Reserve University School of Medicine. "It also avoids the long-term future complications related to metallic stents, such as inability to graft to a fully stented artery in the event that a patient needs coronary artery bypass grafting."

Bezerra and Attizzani have both been involved with the imaging core lab for Absorb studies around the world.  While studying structural cardiology in Italy, Attizzani, a clinical assistant professor, medicine, CWRU School of Medicine, also had opportunity to implant hundreds of Absorb BVS and participate in European studies of the device. The device has been widely used in Europe for about five years.

Abbott is using Bezerra's imaging expertise to teach and train staff and physicians around the world about the importance of vascular imaging and why it makes a difference in the proper deployment technique for Absorb.

For more information: www.abbottvascular.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init